Abstracto

Buccal insulin spray for prandial therapy of Type 1 and Type 2 diabetes

Simona Cernea

Current insulin therapy has some shortcomings, some related to the route of delivery. Subjects with diabetes are still reluctant to initiate/intensify insulin therapy or intentionally omit insulin injections. The buccal spray formulation represents an alternative way of insulin delivery, which offers the advantage of injection-free administration and an improved time-action profile with respect to subcutaneous regular human insulin. Data indicate that the buccal insulin spray is mostly absorbed and the main metabolic effect is obtained in the first 2 h after its application. This article reviews the data from clinical trials published so far, regarding the pharmacology, safety and efficacy and points out the advantages that this formulation may bring in clinical practice.